Infinity Pharmaceuticals Stock Price, News & Analysis (NASDAQ:INFI)

$1.85 -0.01 (-0.54 %)
(As of 02/21/2018 02:00 PM ET)
Previous Close$1.85
Today's Range$1.82 - $1.87
52-Week Range$0.93 - $3.84
Volume213,600 shs
Average Volume595,686 shs
Market Capitalization$94.32 million
P/E Ratio-1.64
Dividend YieldN/A
Beta2.82

About Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals logoInfinity Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers. The Company is also developing IPI-549, which is an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the gamma isoform of PI3K. In addition to duvelisib, the Company focuses to generate new product candidates for potential investigation in oncology. The Company also focuses on developing DYNAMO, CONTEMPO, BRAVURA, FRESCO, DYNAMO+R, DUO, SYNCHRONY and Duvelisib + Venetoclax.

Receive INFI News and Ratings via Email

Sign-up to receive the latest news and ratings for INFI and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:INFI
CUSIP45665G30
Phone617-453-1000

Debt

Debt-to-Equity RatioN/A
Current Ratio5.88%
Quick Ratio5.88%

Price-To-Earnings

Trailing P/E Ratio-1.64347826086957
Forward P/E Ratio-1.99
P/E GrowthN/A

Sales & Book Value

Annual Sales$18.72 million
Price / Sales5.01
Cash FlowN/A
Price / CashN/A
Book Value$1.66 per share
Price / Book1.11

Profitability

Trailing EPS($1.15)
Net Income$-30,100,000.00
Net MarginsN/A
Return on Equity-85.61%
Return on Assets-59.80%

Miscellaneous

Employees23
Outstanding Shares50,710,000

Infinity Pharmaceuticals (NASDAQ:INFI) Frequently Asked Questions

What is Infinity Pharmaceuticals' stock symbol?

Infinity Pharmaceuticals trades on the NASDAQ under the ticker symbol "INFI."

How were Infinity Pharmaceuticals' earnings last quarter?

Infinity Pharmaceuticals Inc. (NASDAQ:INFI) posted its quarterly earnings data on Tuesday, November, 7th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($0.20) by $0.06. The biotechnology company had revenue of $6 million for the quarter, compared to the consensus estimate of $14.70 million. During the same quarter in the previous year, the business posted ($0.39) earnings per share. View Infinity Pharmaceuticals' Earnings History.

When will Infinity Pharmaceuticals make its next earnings announcement?

Infinity Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Monday, March, 12th 2018. View Earnings Estimates for Infinity Pharmaceuticals.

Who are some of Infinity Pharmaceuticals' key competitors?

Who are Infinity Pharmaceuticals' key executives?

Infinity Pharmaceuticals' management team includes the folowing people:

  • Adelene Q. Perkins, Chairman of the Board, Chief Executive Officer (Age 57)
  • Lawrence E. Bloch M.D. J.D., President, Principal Financial Officer, Principal Accounting Officer (Age 52)
  • William C. Bertrand Jr. Esq., Executive Vice President, General Counsel (Age 52)
  • Melissa Hackel, Vice President - Finance
  • Joseph Pearlberg M.D. Ph.D., Vice President - Clinical Development
  • Norman C. Selby, Lead Outside Independent Director (Age 62)
  • Jeffrey Berkowitz J.D., Independent Director (Age 49)
  • Anthony B. Evnin Ph.D., Independent Director (Age 76)
  • Michael G. Kauffman M.D., Ph.D., Independent Director
  • Ian F. Smith CPA, Independent Director (Age 51)

Who owns Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include BVF Inc. IL (19.26%), Platinum Investment Management Ltd. (2.54%), Millennium Management LLC (2.36%), BlackRock Inc. (1.89%), Renaissance Technologies LLC (1.42%) and Geode Capital Management LLC (0.64%). Company insiders that own Infinity Pharmaceuticals stock include Lawrence E Bloch, Michael C Venuti, Sujay Kango and Value Fund L P Biotechnology. View Institutional Ownership Trends for Infinity Pharmaceuticals.

Who sold Infinity Pharmaceuticals stock? Who is selling Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, Platinum Investment Management Ltd. and BlackRock Inc.. View Insider Buying and Selling for Infinity Pharmaceuticals.

Who bought Infinity Pharmaceuticals stock? Who is buying Infinity Pharmaceuticals stock?

Infinity Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Millennium Management LLC, Clear Harbor Asset Management LLC, Wells Fargo & Company MN, Alambic Investment Management L.P., Goldman Sachs Group Inc. and Geode Capital Management LLC. Company insiders that have bought Infinity Pharmaceuticals stock in the last two years include Lawrence E Bloch and Value Fund L P Biotechnology. View Insider Buying and Selling for Infinity Pharmaceuticals.

How do I buy Infinity Pharmaceuticals stock?

Shares of Infinity Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Infinity Pharmaceuticals' stock price today?

One share of Infinity Pharmaceuticals stock can currently be purchased for approximately $1.85.

How big of a company is Infinity Pharmaceuticals?

Infinity Pharmaceuticals has a market capitalization of $94.32 million and generates $18.72 million in revenue each year. The biotechnology company earns $-30,100,000.00 in net income (profit) each year or ($1.15) on an earnings per share basis. Infinity Pharmaceuticals employs 23 workers across the globe.

How can I contact Infinity Pharmaceuticals?

Infinity Pharmaceuticals' mailing address is 784 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-453-1000 or via email at [email protected]


MarketBeat Community Rating for Infinity Pharmaceuticals (INFI)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  226 (Vote Outperform)
Underperform Votes:  251 (Vote Underperform)
Total Votes:  477
MarketBeat's community ratings are surveys of what our community members think about Infinity Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Infinity Pharmaceuticals (NASDAQ:INFI) Analysts' Consensus Rating

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 3.003.003.002.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: N/AN/AN/AN/A
Price Target Upside: N/AN/AN/AN/A

Infinity Pharmaceuticals (NASDAQ:INFI) Consensus Price Target History

Price Target History for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ:INFI) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
10/12/2017Wells Fargo & CoUpgradeMarket Perform -> OutperformN/AView Rating Details
11/10/2016JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/11/2016Morgan StanleyReiterated RatingHold$1.00N/AView Rating Details
8/10/2016FBR & CoReiterated RatingHoldN/AView Rating Details
8/9/2016WedbushReiterated RatingNeutral$1.25 -> $1.00N/AView Rating Details
6/15/2016Jefferies GroupDowngradeBuy -> HoldN/AView Rating Details
6/15/2016William BlairDowngradeOutperform -> Market Perform$20.00 -> $2.00N/AView Rating Details
6/14/2016Royal Bank of CanadaDowngradeOutperform -> Sector Perform$12.00 -> $2.00N/AView Rating Details
6/14/2016JMP SecuritiesDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 2/21/2016 forward)

Earnings

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings History and Estimates Chart

Earnings by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ INFI) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/12/2018($0.25)N/AView Earnings Details
11/7/2017Q3 2017($0.20)($0.14)$14.70 million$6.00 millionViewN/AView Earnings Details
8/3/2017Q2 2017($0.22)($0.34)ViewListenView Earnings Details
5/9/2017Q1 2017($0.22)($0.21)$19.60 million$0.01 millionViewListenView Earnings Details
3/14/2017Q4 2016($0.57)($0.46)$2.33 millionViewN/AView Earnings Details
11/9/2016Q316($0.84)($0.39)$6.23 millionViewListenView Earnings Details
8/9/2016Q216($0.89)$1.05$13.91 million$9.47 millionViewListenView Earnings Details
5/4/2016Q116($0.82)($0.82)$8.80 million$9.26 millionViewListenView Earnings Details
2/23/2016Q415($0.72)($0.80)$18.26 million$9.10 millionViewListenView Earnings Details
11/5/2015Q315($0.76)$0.84$24.85 million$90.70 millionViewN/AView Earnings Details
8/6/2015Q215($1.00)($0.78)$5.83 million$4.90 millionViewN/AView Earnings Details
5/6/2015Q115($1.69)($1.91)$5.79 million$4.40 millionViewListenView Earnings Details
2/24/2015Q414($0.99)($0.83)$5.61 million$4.36 millionViewListenView Earnings Details
11/6/2014Q314($0.87)$2.03$141.40 million$160.60 millionViewListenView Earnings Details
8/5/2014Q114($0.84)($0.78)ViewN/AView Earnings Details
5/6/2014Q1($0.80)($0.87)ViewListenView Earnings Details
2/25/2014Q413($0.87)($0.68)ViewListenView Earnings Details
11/7/2013($0.75)($0.71)ViewN/AView Earnings Details
8/8/2013Q2 2013($0.62)($0.68)ViewListenView Earnings Details
5/7/2013Q1 2013($0.67)($0.57)ViewN/AView Earnings Details
3/5/2013Q4 2012($0.89)($1.15)ViewN/AView Earnings Details
11/6/2012Q312($0.57)$0.52$13.90 millionViewN/AView Earnings Details
8/7/2012Q2 2012($0.38)($0.54)ViewN/AView Earnings Details
5/8/2012Q1 2012($0.37)($0.40)ViewN/AView Earnings Details
3/13/2012Q4 2011($0.42)($0.53)ViewN/AView Earnings Details
11/8/2011Q3 2011($0.40)($0.45)ViewN/AView Earnings Details
8/9/2011Q2 2011($0.36)($0.44)ViewN/AView Earnings Details
5/10/2011Q1 2011($0.36)($0.09)ViewN/AView Earnings Details
3/15/2011Q4 2010($0.39)($0.56)ViewN/AView Earnings Details
11/9/2010Q3 2010($0.76)($0.81)ViewN/AView Earnings Details
8/4/2010Q2 2010($0.32)($0.24)ViewN/AView Earnings Details
5/6/2010Q1 2010($0.34)($0.32)ViewN/AView Earnings Details
2/10/2010Q4 2009($0.42)($0.30)ViewN/AView Earnings Details
11/9/2009Q3 2009($0.44)($0.36)ViewN/AView Earnings Details
8/5/2009Q2 2009($0.52)($0.50)ViewN/AView Earnings Details
5/4/2009Q1 2009($0.08)($0.15)ViewN/AView Earnings Details
2/9/2009Q4 2008$1.01$2.11ViewN/AView Earnings Details
10/29/2008Q3 2008($0.57)($0.63)ViewN/AView Earnings Details
8/4/2008Q2 2008($0.41)($0.57)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.37)$0.02ViewN/AView Earnings Details
2/13/2008Q4 2007($0.27)($0.40)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Estimates

Infinity Pharmaceuticals (NASDAQ:INFI) Earnings Estimates

2018 EPS Consensus Estimate: ($1.10)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181($0.30)($0.30)($0.30)
Q2 20181($0.28)($0.28)($0.28)
Q3 20181($0.27)($0.27)($0.27)
Q4 20181($0.25)($0.25)($0.25)
(Earnings estimates data provided by Zacks Investment Research)

Dividends

Dividend History for Infinity Pharmaceuticals (NASDAQ:INFI)


No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 6.81%
Institutional Ownership Percentage: 52.10%
Insider Trades by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)
Institutional Ownership by Quarter for Infinity Pharmaceuticals (NASDAQ:INFI)

Infinity Pharmaceuticals (NASDAQ INFI) Insider Trades by Quarter

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/6/2017Lawrence E BlochPresidentBuy500,000$1.81$905,000.00580,944View SEC Filing  
10/4/2017Value Fund L P BiotechnologyInsiderBuy1,600,046$1.26$2,016,057.96View SEC Filing  
3/17/2017Michael C VenutiDirectorSell6,250$3.48$21,750.0050,000View SEC Filing  
1/3/2017Value Fund L P BiotechnologyMajor ShareholderBuy4,379$1.34$5,867.86View SEC Filing  
12/30/2016Value Fund L P BiotechnologyMajor ShareholderBuy742,401$1.34$994,817.34View SEC Filing  
12/20/2016Value Fund L P BiotechnologyMajor ShareholderBuy654,921$1.31$857,946.51View SEC Filing  
12/13/2016Sujay KangoInsiderSell75,000$1.28$96,000.0050,590View SEC Filing  
12/12/2016Sujay KangoInsiderSell25,009$1.30$32,511.7050,590View SEC Filing  
12/2/2016Value Fund L P BiotechnologyMajor ShareholderBuy201,394$1.19$239,658.86View SEC Filing  
6/25/2015Adelene Q PerkinsCEOSell5,000$10.93$54,650.00View SEC Filing  
6/15/2015Vito J PalombellaInsiderSell4,737$10.97$51,964.89View SEC Filing  
5/27/2015Adelene Q PerkinsCEOSell10,000$12.81$128,100.00View SEC Filing  
5/14/2015Adelene Q PerkinsCEOSell10,000$12.18$121,800.00View SEC Filing  
3/16/2015Adelene Q PerkinsCEOSell20,000$16.00$320,000.00View SEC Filing  
1/29/2015Adelene Q PerkinsCEOSell20,000$14.83$296,600.00View SEC Filing  
12/15/2014Vito J PalombellaInsiderSell4,737$16.32$77,307.84View SEC Filing  
11/26/2014Vito J PalombellaInsiderSell4,736$15.00$71,040.00View SEC Filing  
9/30/2014Anthony B EvninDirectorSell112,451$13.56$1,524,835.56View SEC Filing  
9/3/2014Vito J PalombellaInsiderSell9,472$15.39$145,774.08View SEC Filing  
11/27/2013Anthony B EvninDirectorSell163,864$14.82$2,428,464.48View SEC Filing  
9/13/2013Adelene PerkinsCEOSell45,000$20.72$932,400.00447,535View SEC Filing  
6/20/2013Vito J PalombellaInsiderSell23,150$18.53$428,969.50View SEC Filing  
11/26/2012Christopher M LindblomInsiderSell13,885$25.73$357,261.05View SEC Filing  
9/7/2012Co BeaconMajor ShareholderBuy5,416,565$14.50$78,540,192.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Infinity Pharmaceuticals (NASDAQ INFI) News Headlines

Source:
DateHeadline
Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release)Notice of Annual General Meeting Copenhagen Stock Exchange:LUN - GlobeNewswire (press release)
globenewswire.com - February 19 at 8:16 AM
Infinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per ShareInfinity Pharmaceuticals Inc. (INFI) Expected to Post Earnings of -$0.25 Per Share
www.americanbankingnews.com - February 15 at 3:16 AM
Mid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses ViewsMid-Morning Market Update: Markets Mostly Lower; Groupon Profit Misses Views
www.nasdaq.com - February 14 at 4:05 PM
Infinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - SlideshowInfinity Pharmaceuticals (INFI) Presents At BIO CEO & Investor Conference - Slideshow
seekingalpha.com - February 13 at 3:44 PM
Infinity To Present At BIO CEO & Investor ConferenceInfinity To Present At BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 9:34 AM
-$0.25 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter-$0.25 Earnings Per Share Expected for Infinity Pharmaceuticals Inc. (INFI) This Quarter
www.americanbankingnews.com - January 29 at 5:12 AM
Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell ...Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination with Immune Checkpoint or Co-Stimulatory Antibodies in B Cell ...
www.businesswire.com - January 26 at 3:43 PM
Infinity Provides Update on Lead Candidate, Issues 2018 ViewInfinity Provides Update on Lead Candidate, Issues 2018 View
www.zacks.com - January 26 at 9:18 AM
Stock Review for Biotechs Investors -- Gilead Sciences, ImmunoGen, Incyte, and Infinity PharmaStock Review for Biotech's Investors -- Gilead Sciences, ImmunoGen, Incyte, and Infinity Pharma
www.prnewswire.com - January 23 at 5:26 PM
Analyzing Iqvia (IQV) and Infinity Pharmaceuticals (INFI)Analyzing Iqvia (IQV) and Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - January 13 at 9:36 PM
Infinity Pharmaceuticals Inc. (INFI) Expected to Announce Earnings of -$0.25 Per ShareInfinity Pharmaceuticals Inc. (INFI) Expected to Announce Earnings of -$0.25 Per Share
www.americanbankingnews.com - January 12 at 7:48 AM
Parkinsons Drug Hits Shelves, Major Event Awaits ABIO In Mar, FDA Nod For NVRO - NasdaqParkinson's Drug Hits Shelves, Major Event Awaits ABIO In Mar, FDA Nod For NVRO - Nasdaq
www.nasdaq.com - January 9 at 6:05 AM
Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance - PR Newswire (press release)Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance - PR Newswire (press release)
www.prnewswire.com - January 8 at 11:18 AM
Infinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial GuidanceInfinity Provides Update on IPI-549 Phase 1/1b Study, 2018 Goals and Financial Guidance
finance.yahoo.com - January 8 at 11:18 AM
Infinity To Present At 36th Annual J.P. Morgan Healthcare ConferenceInfinity To Present At 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 5 at 3:18 PM
 Analysts Anticipate Infinity Pharmaceuticals Inc. (INFI) to Post -$0.25 EPS Analysts Anticipate Infinity Pharmaceuticals Inc. (INFI) to Post -$0.25 EPS
www.americanbankingnews.com - December 9 at 3:12 AM
Ismailia National Food Industries : Fairly valued, but don’t skip the other factorsIsmailia National Food Industries : Fairly valued, but don’t skip the other factors
finance.yahoo.com - December 7 at 3:17 PM
Infinity Pharmaceuticals Inc. (INFI) President Lawrence E. Bloch Acquires 500,000 SharesInfinity Pharmaceuticals Inc. (INFI) President Lawrence E. Bloch Acquires 500,000 Shares
www.americanbankingnews.com - December 7 at 11:30 AM
ValuEngine Downgrades Infinity Pharmaceuticals (INFI) to Strong SellValuEngine Downgrades Infinity Pharmaceuticals (INFI) to Strong Sell
www.americanbankingnews.com - December 3 at 11:06 AM
Options Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) StockOptions Traders Expect Huge Moves in Infinity Pharmaceuticals (INFI) Stock
finance.yahoo.com - November 15 at 2:59 AM
Infinity Pharmaceuticals (INFI) Presents At Society For Immunotherapy Of Cancer - SlideshowInfinity Pharmaceuticals (INFI) Presents At Society For Immunotherapy Of Cancer - Slideshow
seekingalpha.com - November 14 at 12:59 AM
Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549Featured Company News - Infinity Shares Clinical and Translational Data from Monotherapy Dose-Escalation Component of Phase-1/1b Study for IPI-549
finance.yahoo.com - November 13 at 7:56 PM
Today’s Research Reports on Stocks to Watch: Infinity Pharmaceuticals and Synergy PharmaceuticalsToday’s Research Reports on Stocks to Watch: Infinity Pharmaceuticals and Synergy Pharmaceuticals
finance.yahoo.com - November 13 at 7:56 PM
Infinity Pharmaceuticals: When Safety Is A Win - Seeking Alpha - Seeking AlphaInfinity Pharmaceuticals: When Safety Is A Win - Seeking Alpha - Seeking Alpha
seekingalpha.com - November 11 at 12:26 PM
Infinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual MeetingInfinity Pharmaceuticals Reports IPI-549 Clinical and Translational Data from Completed Monotherapy Dose-Escalation Component of Phase 1/1b Clinical Study in Patients with Advanced Solid Tumors at SITC Annual Meeting
finance.yahoo.com - November 11 at 12:26 PM
Edited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMTEdited Transcript of INFI earnings conference call or presentation 9-May-17 8:30pm GMT
finance.yahoo.com - November 11 at 12:26 PM
Short Interest in Infinity Pharmaceuticals, Inc. (INFI) Expands By 178.0%Short Interest in Infinity Pharmaceuticals, Inc. (INFI) Expands By 178.0%
www.americanbankingnews.com - November 11 at 3:40 AM
William Blair Weighs in on Infinity Pharmaceuticals, Inc.s FY2017 Earnings (INFI)William Blair Weighs in on Infinity Pharmaceuticals, Inc.'s FY2017 Earnings (INFI)
www.americanbankingnews.com - November 10 at 2:42 PM
Mid-Morning Market Update: Markets Open Lower; J C Penney Sales Beat EstimatesMid-Morning Market Update: Markets Open Lower; J C Penney Sales Beat Estimates
feeds.benzinga.com - November 10 at 11:19 AM
Infinity Pharmaceuticals, Inc. (INFI) Posts  Earnings Results, Beats Estimates By $0.06 EPSInfinity Pharmaceuticals, Inc. (INFI) Posts Earnings Results, Beats Estimates By $0.06 EPS
www.americanbankingnews.com - November 8 at 7:11 PM
Infinity Pharmaceuticals (INFI) CEO Adelene Perkins on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaInfinity Pharmaceuticals' (INFI) CEO Adelene Perkins on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - November 8 at 10:23 AM
Infinity Provides Company Update and Reports Third Quarter 2017 Financial ResultsInfinity Provides Company Update and Reports Third Quarter 2017 Financial Results
finance.yahoo.com - November 8 at 10:23 AM
Infinity reports 3Q lossInfinity reports 3Q loss
finance.yahoo.com - November 8 at 10:23 AM
Edited Transcript of INFI earnings conference call or presentation 7-Nov-17 1:30pm GMTEdited Transcript of INFI earnings conference call or presentation 7-Nov-17 1:30pm GMT
finance.yahoo.com - November 8 at 10:22 AM
Infinity to Host Investor Reception and Webcast at SITCInfinity to Host Investor Reception and Webcast at SITC
finance.yahoo.com - November 7 at 4:22 AM
Comparing CTI BioPharma Corp. (CTIC) & Infinity Pharmaceuticals (INFI)Comparing CTI BioPharma Corp. (CTIC) & Infinity Pharmaceuticals (INFI)
www.americanbankingnews.com - November 6 at 9:50 PM
Comparing Infinity Pharmaceuticals (INFI) & Intellia Therapeutics (NTLA)Comparing Infinity Pharmaceuticals (INFI) & Intellia Therapeutics (NTLA)
www.americanbankingnews.com - November 1 at 3:12 AM
Infinity Pharmaceuticals, Inc. (INFI) Scheduled to Post Earnings on TuesdayInfinity Pharmaceuticals, Inc. (INFI) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
Infinity Announces the Date of Its Third Quarter 2017 Financial Results Conference Call and WebcastInfinity Announces the Date of Its Third Quarter 2017 Financial Results Conference Call and Webcast
finance.yahoo.com - October 30 at 10:10 PM
Infinity, Wells Fargo Upgrade, SITC Meeting in November, IPI-549 UpdateInfinity, Wells Fargo Upgrade, SITC Meeting in November, IPI-549 Update
finance.yahoo.com - October 23 at 7:33 PM
Infinity Pharmaceuticals, Inc. - StreetInsider.comInfinity Pharmaceuticals, Inc. - StreetInsider.com
www.streetinsider.com - October 18 at 1:29 AM
Infinity Pharmaceuticals, Inc. (INFI) Stock Rating Upgraded by Wells Fargo & CompanyInfinity Pharmaceuticals, Inc. (INFI) Stock Rating Upgraded by Wells Fargo & Company
www.americanbankingnews.com - October 15 at 8:30 AM
Infinity Pharma (INFI) Announces IPI-549 Late-Breaking Presentation at SITCInfinity Pharma (INFI) Announces IPI-549 Late-Breaking Presentation at SITC
www.streetinsider.com - October 13 at 7:42 PM
Infinity Announces IPI-549 Late-Breaking Presentation at SITC Annual MeetingInfinity Announces IPI-549 Late-Breaking Presentation at SITC Annual Meeting
finance.yahoo.com - October 13 at 7:42 PM
Infinity Pharma up big but news scarce; shares ahead 90% - Seeking AlphaInfinity Pharma up big but news scarce; shares ahead 90% - Seeking Alpha
seekingalpha.com - October 13 at 2:33 AM
Why Infinity Pharmaceuticals Shares Are Surging - 24/7 Wall St.Why Infinity Pharmaceuticals Shares Are Surging - 24/7 Wall St.
247wallst.com - October 13 at 2:33 AM
Mid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher - NasdaqMid-Afternoon Market Update: Crude Oil Down 2%; Infinity Pharmaceuticals Shares Spike Higher - Nasdaq
www.nasdaq.com - October 13 at 2:33 AM
Infinity Pharmaceuticals: Oral Presentation Implies Near-Term Upside - Seeking AlphaInfinity Pharmaceuticals: Oral Presentation Implies Near-Term Upside - Seeking Alpha
seekingalpha.com - October 13 at 2:33 AM
Infinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference PresentationInfinity Pharmaceuticals Notches Upgrade Ahead Of Cancer Conference Presentation
finance.yahoo.com - October 13 at 2:33 AM
Infinity Pharmaceuticals, Inc. (INFI) Upgraded to Sell at ValuEngineInfinity Pharmaceuticals, Inc. (INFI) Upgraded to Sell at ValuEngine
www.americanbankingnews.com - October 12 at 11:16 PM

SEC Filings

Infinity Pharmaceuticals (NASDAQ:INFI) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Infinity Pharmaceuticals (NASDAQ:INFI) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Infinity Pharmaceuticals (NASDAQ INFI) Stock Chart for Wednesday, February, 21, 2018

Loading chart…

This page was last updated on 2/21/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.